Impact of DNMT3A and IDH1/IDH2 Mutations on Treatment Response with Azacitidine in Myeloid Neoplasms. (April 2017) - Martín, I.; Navarro, B.; Such, E.; Calabuig, M.; Villamón, E.; Sanz, G.; Cervera, J.; Amat, P.; García, F.; Serrano, A.; Mora, E.; Regadera, A.; et al.